The Rockefeller University: Research to Revenue

The Rockefeller University

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 0 commercialization opportunities from The Rockefeller University and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of The Rockefeller University's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

63/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

8/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

63/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1901

First Nobel

1976

First Patent

1929

First IPO

N/A

2022-2024

AI-driven diagnostics

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1928

Insulin Patent

First insulin-related patent granted

1928

Monoclonal Antibodies

Developed hybridoma technology

1950s

DNA Sequencing

Advanced DNA sequencing methods

1970s

HIV Research

Identified key HIV proteins

1980s

Cancer Therapeutics

Developed novel cancer drugs

2000s

Competitive Benchmarking

The Rockefeller University vs. Peer Research Universities

The Rockefeller University vs Peers Comparison

Metric	The Rockefeller University (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$385M	$855M	$1,675M
New Inventions Disclosed	11	200	400
Startups Formed	2	7	10
Visibility Index	16	12	23
Licensing Revenue	$10M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Precision Immunotherapy Innovations Targeting Cancer with Rockefeller's Unique Antibody Engineering

Revolutionizing cancer treatment by developing highly specific antibodies, addressing treatment resistance, and significantly improving patient outcomes globally in a scalable immunotherapy market.

2. Cutting-Edge Neurodegenerative Disease Biomarkers for Early Diagnosis and Intervention

Early detection biomarkers for Alzheimer's and Parkinson's enable timely treatment, reducing healthcare costs and improving patient quality of life in a rapidly growing market.

3. Synthetic Biology Platforms Accelerating Vaccine Development and Personalized Medicine

Scalable synthetic biology tools streamline vaccine creation and individualized therapies, addressing urgent global health needs with competitive speed and precision.

4. Advanced Single-Cell Analysis Technologies Unlocking Cellular Mechanisms for Drug Discovery

Innovative single-cell platforms provide deep insights into disease biology, enhancing drug development efficiency and precision across multiple therapeutic areas.

5. Novel Anti-Inflammatory Therapeutics Derived from Rockefeller’s Molecular Immunology Research

Targeting chronic inflammation, these therapeutics address widespread diseases, offering scalable solutions with strong differentiation in a high-demand pharmaceutical market.

6. Breakthrough Structural Biology Techniques Enabling Rational Drug Design and Biologics Optimization

State-of-the-art structural analysis accelerates drug candidate optimization, reducing time-to-market and increasing success rates in competitive biopharmaceutical development.